Market Overview

Koutif Therapeutics Confirms Clinical Candidate Drug


Company Expects to File IND Application in Late 2018

Koutif Therapeutics today announced that KT-1002, which has been
selected as its lead compound, has reached clinical candidate status for
the treatment of inflammatory bowel disease, including ulcerative
colitis and Crohn's Disease, after successfully completing IND-enabling
studies. The biotech start-up's small molecule oral inhibitor of Fbxo3,
an E3 ligase, also shows promise in the treatment of multiple
inflammatory condition targets, including bronchiolitis obliterans
syndrome, chronic obstructive pulmonary disease, acute lung injury, and
rheumatoid arthritis.

"We are very encouraged by the results of the lead compound both in
IND-enabling studies as well as in disease models," said Baiju R. Shah,
CEO of BioMotiv and Chairman of Koutif Therapeutics. "Based on the data,
we plan to file an IND application by the end of the year."

Koutif Therapeutics has exclusively licensed intellectual property,
which includes the lead compound KT-1002, from the University of
Pittsburgh and the United States Department of Veterans Affairs. KT-1002
was developed by Rama K. Mallampalli, MD, Professor and Chief of the
Pulmonary, Allergy and Critical Care Division at the University of
Pittsburgh School of Medicine and Staff Physician at the VA Pittsburgh
Healthcare System, and Beibei Chen, PhD, Associate Professor of
Medicine, Director, Small Molecule Therapeutic Center, Co-director,
Acute Lung Injury Center of Excellence at the University of Pittsburgh
School of Medicine, each of whom hold equity in Koutif Therapeutics and
serve as paid consultants to the company.

The intellectual property licensed from Pitt includes several compounds
that potently inhibit the novel target Fbxo3. KT-1002 causes degradation
of several potent, pro-inflammatory proteins, including multiple
proteins involved in adaptive and innate signaling pathways. This novel
mechanism has the potential to treat numerous inflammatory conditions.

The intellectual property derived from research funded by multiple
Department of Veterans Affairs Merit Awards and NIH grants, including
the prestigious NIH CADET grant awarded to Dr. Mallampalli in 2014. Dr.
Mallampalli has also received support from Harrington Discovery
Institute, which is supported in part by a grant from the Ohio Third
Frontier, as a 2016 Harrington Scholar-Innovator.

Click here
to learn more about Koutif Therapeutics.

About BioMotiv

BioMotiv is the mission-driven accelerator associated with The
Harrington Project for Discovery & Development, a $340 million
initiative for advancing medicine centered at University Hospitals in
Cleveland. The focus is to accelerate breakthrough discoveries from
research institutions into therapeutics for patients through an
innovative model that efficiently aligns capital and collaborations. The
company leverages an experienced team and advisory board to select,
fund, and actively manage and advance a portfolio of drug development

For more information, go to:

About The Harrington Project for Discovery & Development

The Harrington Project for Discovery & Development (The Harrington
Project) is a $340 million national initiative built to bridge the
translational valley of death. It includes the Harrington Discovery
Institute at University Hospitals in Cleveland and BioMotiv, a
for-profit, mission-aligned drug development company that accelerates
early discoveries into medicines for benefit of society.

For more information about The Harrington Project and the Harrington
Discovery Institute, visit:

About University of Pittsburgh

The University of Pittsburgh is one of the nation's leading research
universities with expertise across a broad range of academic
disciplines. The University seeks to achieve positive societal impact
through the commercial licensing of innovations developed from sponsored
research. To learn more about Pitt innovations available for licensing
or contact the Innovation Institute at

View Comments and Join the Discussion!